EmaxHealth Health News
Home » Men's Health » Prostate Cancer Treatment and Symptoms

Regular PSA Screening May Be Dscontinued In Certain Elderly

Ads by Google

All About:
  • Prostate Cancer Treatment and Symptoms

By Armen Hareyan on May 15, 2008 - 7:10am for eMaxHealth

Men aged 75-80 with prostate-specific antigen (PSA) levels less than 3 ng/ml may be able to discontinue their regular prostate cancer screenings, according to new research presented today during the Annual Scientific Meeting of the American Urological Association (AUA).

Johns Hopkins University researchers found that men in this age group who had a PSA level of 3 ng/ml or above had an increasing probability of death from prostate cancer in their remaining life, while men with lower PSA levels did not.

Researchers presented their findings to the media during a special press conference on May 21, 2008 at 11:00 a.m.

It is well known that prostate cancer screening is an important part of health maintenance and is very effective in detecting the disease at its most treatable stages in men who are regularly screened. However, prostate cancer can be slow growing and is not always aggressive enough to require immediate treatment. In older patients with shorter life expectancies, a non-aggressive, screen-detected cancer can result in increased stress and, possibly, unnecessary treatment. Researchers sought to determine a safe cut off for annual screening of older men based on PSA levels and an individual's probability of developing deadly prostate cancer in their remaining life.

Using a cohort of 849 participants in the Baltimore Longitudinal Study of Aging - 122 with prostate cancer and 727 men without the disease - Johns Hopkins researchers examined the proportion of men with aggressive prostate cancer by PSA and age to evaluate the safety of discontinuing PSA testing among older men. Study participants were aged 75-80 and were divided into two groups by PSA (3 ng/ml or above, and below 3 ng/ml).

Researchers compared multiple outcomes: probability of death from prostate cancer, death from prostate cancer, Gleason score 8 or above at diagnosis or PSA 20 ng/ml or above at diagnosis. Participants who presented with a PSA of at least 3 ng/ml had an increasing probability of death from prostate cancer, while men in the same age group with a PSA below 3 ng/ml did not share this risk. From these results, researchers conclude that it may be safe to discontinue regular testing in men ages 75-80 with PSA levels below 3 ng/ml as they are unlikely to develop aggressive disease during their remaining life.

Source: 
American Urological Association

eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.

  • Add new comment

Similar Stories

  • Prostate Size May Provide Clues in Predicting Severity of Cancer
  • Scientists Say Nuts to Prostate Cancer
  • Dutasteride may slow prostate cancer, but questions remain
  • Natural formula shows promise for aggressive prostate cancer
  • Mass prostate cancer screening catches more tumors, doesn't reduce deaths

 Dr. Oz Promotes Magnet Cure
 Skin Care Secrets in Your Kitchen
 3 Gadgets to Make You Look 10 Years Younger
 Catalase is the Culprit for Gray Hair
 Vibration Therapy Helps Chronic Pain
 What If Antidepressants Don't Work
 When Obesity is OK for Some

Health Categories

 EMAXHEALTH HOME
 AFFORDABLE HEALTH INSURANCE
 DIET & WEIGHT LOSS
 FITNESS & EXERCISE
 MEN'S HEALTH
 WOMEN'S HEALTH
 BEAUTY
 ALTERNATIVE MEDICINE
 CANCER TREATMENT
 AGING
 DISEASE and CONDITION
 MENTAL HEALTH
 GENERAL HEALTH
 PERSONAL HEALTH
 GOURMET FOOD & HEALTH
 HEALING & SPIRITUALITY
 MONEY AND HEALTH
 Comment Moderation
  • Health RSS Feeds
  • Privacy Policy
  • Disclaimer
  • About Us
  • Editorial Review Process
  • Advertise
  • Contact
  • Contributors
Copyright eMaxhealth.com 2005-2012. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.